Loading…
← CockpitCompetitor Analysis › 603351.SS Nanjing Well Pharmaceutical Group Co. Ltd. Class AOpen in the cockpit ↗

Nanjing Well Pharmaceutical Group Co. Ltd. Class A603351.SSCompetitor analysis, valuation and peers

China · CNY·Materials›Chemicals: Major Diversified
Momentum leader 89
Mkt cap
$550M
US dollars, full cap
Free float
46%
of shares outstanding
$/day
$8.24M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
+3.5 pp
WACC 7.1%
Hurdle
-10 pp
Req g minus delivered
Close · CNYCN¥26.96
1D-2.9%
1W-4.4%
1M+0.4%
3M+0.5%
6M-2.1%
YTD+3.6%
1Y-5.7%
ATR %3.8%
52w lowhigh12.5% off high

What Nanjing Well Pharmaceutical does

Employees: 718

Nanjing Well Pharmaceutical at a glance

Size Nanjing Well Pharmaceutical (603351.SS) is a China Materials company (Chemicals: Major Diversified) with a market value of $550M, the 3462nd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥26.96 on 18 Nov 2026.

Performance Over six months the shares fell 2.1%, against -19.1% for the median peer and -20.0% for the China market (cap-weighted) — 3rd highest of 20 in its peer set.

Growth Revenue grew 6.5% over the last twelve months (peer median +7.9%); the operating margin is 13.1% (peer median 7.2%).

Valuation It trades at 2.7× enterprise value to sales against a peer median of 2.9× (11th cheapest of 21).

Price implies For today's price to make sense, revenue must grow about 3% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -10 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 3.5 points above its cost of capital (7.1% WACC).

Relative performance

809010021 May 202621 Aug 202618 Nov 2026603351.SS 99Peer median 84
Six months, rebased to 100: Nanjing Well Pharmaceutical against the median of its 20 peers (local-currency closes).

Nanjing Well Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.40BCN¥1.33BCN¥1.29BCN¥1.15BCN¥1.11B
Revenue growth—+3%+12%+4%—
Gross profitCN¥470MCN¥349MCN¥332MCN¥290MCN¥280M
EBITDAn/aCN¥309MCN¥285MCN¥205MCN¥190M
Net incomeCN¥157MCN¥151MCN¥146MCN¥112MCN¥95.0M
Free cash flowCN¥208MCN¥186MCN¥171MCN¥47.2M-CN¥124M
Capital expenditureCN¥67.1MCN¥52.2MCN¥51.5MCN¥73.1MCN¥234M
Total debtCN¥331MCN¥575MCN¥481MCN¥499MCN¥454M

Quarterly statements and history in the cockpit →

Nanjing Well Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-40%-20%0%+20%300839300537688267688669002783ACI3008016030046887503000556032854972600165300214FOSECOINDQES301206603351.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Nanjing Well Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%2×4×6×300839300537688267688669002783ACI3008016030046887503000556032854972600165PRASOLCHEM1723300214FOSECOINDQES301206603351.SSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Nanjing Well Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%3008393005376886690027833008016030046887504972PRASOLCHEM1723300214FOSECOIND603351.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Nanjing Well Pharmaceutical is the large dot.

Nanjing Well Pharmaceutical competitors and peer comparison

How Nanjing Well Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Nanjing Well Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure603351.SSPeer medianRank in peer set
1-month return+0.4%-11.1%4th highest of 21
6-month return-2.1%-19.1%3rd highest of 20
Distance from 52-week high-12.5%-41.4%2nd highest of 21
Revenue growth (TTM)+6.5%+7.9%10th lowest of 21
Operating margin13.1%7.2%7th highest of 21
EV / Sales2.7×2.9×11th cheapest of 21
Growth the price implies (Req g, 7 yrs)3.0%11.7%4th least demanding of 13
Growth delivered (Del g)+12.7%+11.2%6th highest of 13
Hurdle (Req g minus delivered)-9.7 pp+4.6 pp4th least demanding of 13
ROIC minus cost of capital+3.5 pp+0.2 pp5th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Nanjing Well Pharmaceutical 603351.SSChina$550M-2%+7%13%2.7×3.0%+12.7%
Ningbo Bohui Chemical Technology 300839.SZChina$533M-35%+42%4%1.0×1.2%+23.1%
Jiangsu Kuangshun Photosensitivity New Material Stock 300537.SZChina$568M-33%+15%6%6.5×41.7%-8.5%
China Catalyst 688267.SSChina$532M-38%-3%18%3.4×n/an/a
Polyrocks Chemical 688669.SSChina$529M-16%-8%-6%1.6×27.6%+15.2%
Hubei Kailong Chemical 002783.SZChina$528M-18%-2%8%1.8×-2.9%+12.0%
Archean Chemical Industries ACI.NSIndia$576M-19%+6%12%5.0×n/an/a
Shandong Taihe Technologies 300801.SZChina$582M-42%-2%7%1.2×5.2%+12.9%
Zhejiang Dragon Technology 603004.SSChina$582M-22%-11%16%4.2×15.8%+1.7%
Hunan Xiangtou Goldsky Titanium Industry Technology 688750.SSChina$585M-29%+4%6%6.2×28.9%-4.3%
Beijing WBD New Materials 300055.SZChina$512M-56%+13%-9%1.7×n/an/a
Shandong Jianbang New Material 603285.SSChina$594M-50%+8%22%4.8×n/an/a
Soken Chemical & Engineering 4972.TJapan$507M+54%+11%14%1.3×-1.2%+8.8%
Ningxia Zhongke Biotechnology 600165.SSChina$601M-17%+8%-73%7.7×n/an/a
Prasol Chemicals PRASOLCHEM.NSIndia$496Mn/a+22%10%3.8×24.8%+15.8%
China Steel Chemical 1723.TWTaiwan$484M-11%+8%12%2.5×3.7%+1.6%
Shandong Rike Chemical 300214.SZChina$483M-9%-6%2%1.3×7.5%+10.5%
Anhui Huaertai Chemical 001217.SZChina$482M-16%+13%-3%1.6×n/an/a
Foseco India FOSECOIND.NSIndia$476M+21%+47%18%5.1×27.8%+20.7%
China Sunsine Chemical QES.SISingapore$474M-9%+4%14%0.3×n/an/a
Shandong Sanyuan Biotechnology 301206.SZChina$644M-21%+15%4%3.7×n/an/a

Questions

Which companies are Nanjing Well Pharmaceutical's closest peers?
The cockpit's peer set: Ningbo Bohui Chemical Technology (300839.SZ), Jiangsu Kuangshun Photosensitivity New Material Stock (300537.SZ), China Catalyst (688267.SS), Polyrocks Chemical (688669.SS), Hubei Kailong Chemical (002783.SZ), Archean Chemical Industries (ACI.NS), Shandong Taihe Technologies (300801.SZ), Zhejiang Dragon Technology (603004.SS).
Is Nanjing Well Pharmaceutical expensive compared with its peers?
On ev / sales it trades at 2.7× against a peer median of 2.9×, 11th cheapest of 21 in its peer set. For today's price to make sense, revenue must grow about 3% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -10 pp: the price already allows for a slowdown.
How has Nanjing Well Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -2.1% against -19.1% for the median peer; over one year -5.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.